Ziad Younes
About
In The Last Decade
Ziad Younes
65 papers receiving 1.8k citations
Hit Papers
Peers
Comparison fields: 5 of 81
- Epidemiology 1.3k
- Hepatology 882
- Surgery 345
- Genetics 237
- Endocrinology, Diabetes and Metabolism 228
Countries citing papers authored by Ziad Younes
This map shows the geographic impact of Ziad Younes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ziad Younes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ziad Younes more than expected).
Fields of papers citing papers by Ziad Younes
This network shows the impact of papers produced by Ziad Younes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ziad Younes. The network helps show where Ziad Younes may publish in the future.
Co-authorship network of co-authors of Ziad Younes
This figure shows the co-authorship network connecting the top 25 collaborators of Ziad Younes. A scholar is included among the top collaborators of Ziad Younes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ziad Younes. Ziad Younes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 16 | |
| 2 | 18 | |
| 3 | Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis breakdown → | 218 |
| 4 | 5 | |
| 5 | 64 | |
| 6 | 1 | |
| 7 | Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study | 5 |
| 8 | 110 | |
| 9 | 21 | |
| 10 | 10 | |
| 11 | 133 | |
| 12 | 22 | |
| 13 | 3 | |
| 14 | 19 | |
| 15 | 68 | |
| 16 | 2 | |
| 17 | 21 | |
| 18 | 12 | |
| 19 | 4 | |
| 20 | 2 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.